Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SNSE Sensei Biotherapeutics
1.470-0.040-2.65%
Close
02/03 16:00 ET
High
1.550
Open
1.490
Turnover
66.85K
Low
1.465
Pre Close
1.510
Volume
45.12K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
CrowdStrike Holdings, Coinbase Global, GDS Holdings Among Premarket Losers' Pack
Sensei Biotherapeutics Enters Clinical Supply Agreement With Regeneron For Libtayo
Sensei Biotherapeutics Announces Clinical Supply Agreement With Regeneron For Phase 1/2 Clinical Trial Evaluating SNS-101, A Conditionally Active VISTA-Blocking Antibody, in Combination With Libtayo Ij Solid Tumors
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced a clinical supply agreement
Citigroup Initiates Sensei Biotherapeutics at Buy Rating
11:58 AM EST, 12/13/2022 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Newman Ferrara LLP Announces Corporate Governance Investigations of Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics (NASDAQ:SNSE) & Atreca (NASDAQ:BCEL) Financial Review
Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) and Atreca (NASDAQ:BCEL – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses bas
Sensei Biotherapeutics to Shutter Boston Research Site, Lay Off 40% of Staff
01:53 PM EST, 12/08/2022 (MT Newswires) -- Sensei Biotherapeutics (SNSE) said Thursday it will shutter its Boston research site and cut its staff by nearly 40% as part of efforts to realign its resour
Sensei Biotherapeutics Slashes Workforce, Closes R&D Site
Sensei Biotherapeutics Inc (NASDAQ:SNSE) announced a streamlining and realignment of resources.The company will close its Boston research site and reduce its workforce by approximately 40% to extend S
Sensei Plans to Submit IND Application for SNS-101 in or Prior to April
Sensei Biotherapeutics Appoints Edward Van Der Horst as CSO
Company Overview
More
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Boston, MA.
CEO： Mr. John Celebi
Market： NASDAQ
Listing Date： 02/04/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet